What are new treatment concepts in systemic itch?

Area of Science:

• Dermatology
• Nephrology
• Gastroenterology
• Pharmacology

Background:

• Chronic pruritus significantly impacts patients with systemic diseases, including chronic kidney disease (CKD), hepatobiliary disorders, and hematological conditions.
• It is also associated with adverse drug reactions, presenting a complex clinical challenge.

Purpose of the Study:

• To review recent advancements in pharmacological treatments for chronic pruritus.
• To highlight novel therapeutic targets and drugs in various stages of development for systemic diseases associated with pruritus.

Main Methods:

• Review of current literature on pharmacological interventions for chronic pruritus.
• Analysis of drugs targeting specific pathways, including opioid receptors, calcium channels, neurokinin-1 receptors, and ileal bile acid transporters (IBAT).

Main Results:

• µ-opioid receptor antagonists are established treatments, while k-opioid receptor agonists like nalfurafine are approved for specific conditions (e.g., CKD-associated pruritus).
• Gabapentin and pregabalin show efficacy for pruritus in internal diseases, particularly CKD-associated pruritus.
• Neurokinin-1 receptor antagonists and IBAT inhibitors are under investigation for various pruritic conditions.

Conclusions:

• Emerging therapies targeting novel pathways offer promising treatment options for chronic pruritus.
• Ongoing clinical trials and drug development provide hope for improved management of pruritus in systemic diseases.